Hongyuan Pharmaceutical released its 2026 interim report on August 27. First-half operating revenue was 1.342 billion yuan, up 52.1 percent year on year. Net profit attributable to the parent successfully swung to a profit of 156 million yuan, compared with a loss of 5.81 million yuan in the same period last year. Net profit attributable to the parent after deducting non-recurring items was 159 million yuan, compared with a loss of 21.59 million yuan a year earlier. Net operating cash flow was 39.52 million yuan, up 123.3 percent year on year. In the second quarter, operating revenue was 638 million yuan, up 42.2 percent year on year, and net profit attributable to the parent was 11.89 million yuan, compared with a loss of 14.7 million yuan in the same period last year. The company focuses on pharmaceuticals and lithium battery materials, and plans to expand into pharmaceutical preparations, strengthen the competitiveness of its lithium hexafluorophosphate business, and lay out products such as electrolyte additives.
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. AHongyuan Pharmaceutical swung to a first-half net profit of 156 million yuan from a year-earlier loss, with revenue up 52.1%.
